Navigation Links
Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
Date:11/16/2009

BOSTON, Nov. 16 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)." Apoptone (HE3235), a novel steroid that is an analog of a dihydrotestosterone metabolic pathway member, stimulates cell death (apoptosis) in hormone-dependent prostate tumors. Presenting the data is the lead investigator of the study, R. Bruce Montgomery, M.D., Associate Professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine. The poster also included supportive preclinical data.

The interim results of the Phase I/II study, which is being conducted with participating member sites of the Prostate Cancer Clinical Trial Consortium (PCCTC), demonstrated that 47% of subjects who were radiographically evaluable for response had stable disease. With the assessment of progression every 56 days, the median time to progression was 107 days. Forty-three percent of the biochemically evaluable subjects experienced a drop in PSA during treatment, with 33% equal to or greater than a 50% decline.

Individuals experienced increases in PSA with stable disease. Plasma PSA increases are expected because the mechanism of action is believed to involve inhibition of tumor cell proliferation while the androgen receptor transcription element is engaged, independent of the androgen receptor.
'/>"/>

SOURCE Hollis-Eden Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
2. Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price
3. Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
4. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
5. Curemark Presents at Springboard Enterprises Life Sciences Forum
6. NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
7. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
8. DIATHERIX Laboratories Presents at Homeland Security Conference
9. Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
10. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
11. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  Prima Biomed Ltd. ... that is striving to become a leader in the ... recently announced that the final CVac data from the ... a clear trend for a clinically meaningful improvement in ... second remission patients. In the group of ...
(Date:5/21/2015)... Imagine being able to probe and truly ... Being able to read faces and enjoy genuine invisible ... their thoughts and actions like never before. Use ... unique abstract paintings and video, or, play a completely ... as it creates action, dialog, and outcomes based on ...
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: ... on the development of autologous cell therapies, announced ... Society for Cellular Therapy (ISCT) on RepliCel,s autologous ... a Phase 1/2 clinical trial.  The presentation, taking ... PM to 7:00 PM local time, will review ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
... Va., June 27, 2011 A Continuing Medical Education (CME) ... of key risk factors , will be hosted at the ... 2011 from 8:30am to 1pm. "Beating ... Education credits, is designed to help doctors eradicate this disease ...
... JUPITER, Fla., June 27, 2011 Dyadic International, ... company focused on the discovery, development, manufacture and ... industrial enzyme, bioenergy, and biopharmaceutical industries, announced today ... development and license agreement with a key provider ...
... PharmacoFore, Inc., a privately held biopharmaceutical company developing ... Dr. Joseph Stauffer as Chief Medical Officer & VP, ... Property. Dr. Joseph Stauffer ... Prior to joining PharmacoFore, Dr. Stauffer ...
Cached Biology Technology:Health Diagnostic Laboratory Inc. Sponsors Lecture Series in West Palm Beach, Florida 2Dyadic International Enters Into Research and License Agreement With Major Player in the Animal Feed Industry 2Dyadic International Enters Into Research and License Agreement With Major Player in the Animal Feed Industry 3PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property 2PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property 3PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property 4
(Date:5/19/2015)... , May 19, 2015  Technology is rapidly ... internally and in the cloud. Passwords and their management ... of OTP and standards-based specifications such as those developed ... outmoded use of passwords presents for BYOD, COPE, IoT, ... unified biometric identity protocol. In response ...
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
(Date:5/11/2015)...  Through a well-rounded UAS delegation representing private industry, government, ... showing at AUVSI,s Unmanned 2015 conference last week in ... UAS industry met with over 200 hundred people ... the UAS ecosystem. "Our message is clear ... Aerospace Rich Knoll . "If you want to fly ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... the University of Houston for a two-day conference to discuss ... , The UH Texas Obesity Research Center (TORC) ... UH M.D. Anderson Library, Rockwell Pavilion. , "We ... that others will see the wealth of obesity research that ...
... hopeful moms-to-be learn, there are important considerations to the ... environment, regular hormonal injections and the timing of the ... procedure. Now a Tel Aviv University researcher ... look at the role that gravity and other biomechanical ...
... team of scientists led by the UK has been given ... frontiers - an ancient lake hidden deep beneath Antarctica,s ice ... the size of Lake Windermere (UK) may have been ... unique forms of life. The team hopes the exploration will ...
Cached Biology News:Texas Obesity Research Center at UH assembles researchers to discuss obesity 2Engineering bouncing babies, 1 at a time 2Final frontier: Mission to explore buried ancient Antarctic lake given green light 2
... The European Collection of Cell Cultures (ECACC) ... West of the West of England, Bristol, ... the quality control of HER2, oestrogen and ... paraffin wax sections of formalin fixed, breast ...
... Electro-4 design allows "4 gels in one ... possible to run 200,samples or more in ... to four,horizontal gels. To ensure even migration, ... number of gels being run. Ideal for,high ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
... several isoprostanes produced from arachidonic acid during lipid ... the rat. 8-iso PGE2 inhibits U-46619 or I-BOP-induced ... 5 µM, respectively. When infused into the renal ... 4 mg/kg/min, 8-iso PGE2 decreases the GFR and ...
Biology Products: